Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

18 marzo 2019 aggiornato da: Merck Sharp & Dohme LLC

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial With a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

The purpose of this study is to assess the safety and efficacy of MK-8457 + Methotrexate (MTX) in participants with active rheumatoid arthritis (RA) despite MTX therapy. The primary hypothesis is that at least 1 dose of MK-8457 + MTX will be superior to placebo + MTX as measured by the percentage of participants who achieve American College of Rheumatology 20 (ACR 20) response after 12 weeks of treatment.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

In Base Study Phase IIa, participants were to receive blinded MK-8457 100 mg or matched placebo for up to 24 weeks. At Week 12 and 18 of Phase IIa, efficacy evaluation was conducted to assess eligibility for early escape, defined as <20% reduction in both tender and swollen joint counts. The study plan included Base Study Phase IIb in which dose range finding or dose-response was to be evaluated, depending on the outcome of Phase IIa. Participants who completed Phase IIa or Phase IIb and those eligible for early escape could enroll in Period 3, a 2-year Safety Extension.

All participants must have been treated with MTX for at least 3 months prior to screening and have been receiving a stable dose of MTX for at least 4 weeks prior to screening.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

82

Fase

  • Fase 2

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Diagnosis of rheumatoid arthritis for at least 6 months prior to screening
  • Active rheumatoid arthritis as defined by the presence of >= 6 swollen joints (of 66 count) and >= 6 tender joints (of 68 joint count)
  • C-reactive protein blood level >0.9 mg/dL
  • Anti-citrullinated protein antibody positive and/or rheumatoid factor positive at screening
  • American College of Rheumatology Functional Class I, II, or III
  • Received methotrexate for a minimum of 3 months prior to screening with a regionally appropriate stable weekly dose for at least 4 weeks prior to screening
  • If using oral corticosteroids, the participant must be on a stable dose of 10 mg prednisone
  • No history of either untreated, latent, or active tuberculosis prior to baseline
  • Participants of reproductive potential must agree to remain abstinent or use 2 acceptable methods of birth control

Exclusion Criteria:

  • Presence of inflammatory disease other than rheumatoid arthritis, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease
  • Positive hepatitis B surface antigen or hepatitis C test result or the presence of Human immunodeficiency virus (HIV) infection
  • HIV positive
  • User of recreational or illicit drugs or has had a history (within the previous 2 years) of drug or alcohol abuse or dependence
  • Females of childbearing potential who are pregnant, intend to become pregnant, or are lactating;
  • Severe opportunistic infection within 6 months prior to study start.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Base Study Phase IIa: MK-8457
Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
Droga: MK-8457 100 mg
MK-8457 100 mg dosato per via orale BID
Droga: Methotrexate
MTX dosed at the stable dose receive upon study entry
Altri nomi:
  • MTX
Comparatore placebo: Base Study Phase IIa: Placebo
Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
Droga: Methotrexate
MTX dosed at the stable dose receive upon study entry
Altri nomi:
  • MTX
Droga: Dose-Matched Placebo
Dose-matched placebo dosed orally BID
Sperimentale: Safety Extension Period 3: MK-8457
Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
Droga: MK-8457 100 mg
MK-8457 100 mg dosato per via orale BID
Droga: Methotrexate
MTX dosed at the stable dose receive upon study entry
Altri nomi:
  • MTX

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentuale di partecipanti che hanno ottenuto una risposta 20 dell'American College of Rheumatology (ACR) alla settimana 12
Lasso di tempo: Settimana 12
Le risposte ACR sono misurazioni numeriche del miglioramento in più criteri di valutazione della malattia. Una risposta ACR20 è definita come un miglioramento ≥20% in 1) conta delle articolazioni gonfie (66 articolazioni) e conta delle articolazioni dolenti (68 articolazioni) (0 = Assente; 1 = Presente) e 2) miglioramento ≥20% in 3 dei seguenti 5 valutazioni: a) la valutazione complessiva del dolore di un partecipante su una scala analogica visiva (VAS, nessun dolore = 0 a dolore estremo = 100); b) Valutazione globale del paziente dell'attività della malattia VAS (da molto bene =0 a molto scarso =100); c) Valutazione globale dell'attività della malattia da parte dello sperimentatore VAS (facendo molto bene = 0 a facendo molto male = 100; d) valutazione della funzione del partecipante in 8 aree funzionali misurata dal questionario di valutazione della salute (HAQ), punteggi totali che vanno da nessuna difficoltà = 0 all'incapacità di svolgere compiti =24; e e) proteina C-reattiva sierica (la diminuzione indica un miglioramento). Questa misura dell'esito si applicava solo ai partecipanti allo studio di base.
Settimana 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Disease Activity Score (DAS28) as Measured by Erythrocyte Sedimentation Rate (ESR) at Week 12
Lasso di tempo: Baseline and Week 12
The DAS28-ESR is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), ESR (an inflammatory marker), and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-ESR = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.70 × ln (ESR) + 0.014 × GH. SQRT = square root. The DAS28-ESR is a scale ranging from 0 to 10 with higher values indicating greater rheumatoid arthritis (RA) disease activity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in DAS28 as Measured by C-Reactive Protein (CRP) at Week 12
Lasso di tempo: Baseline and Week 12
The DAS28-CRP is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), CRP (an inflammatory marker), and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-CRP = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.36 × ln (CRP+1) + 0.014 × GH + 0.96. The DAS28-CRP is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Percentage of Participants Achieving an ACR70 Response at Week 12
Lasso di tempo: Week 12
ACR responses are numerical measurements of improvement in multiple disease assessment criteria. An ACR70 response is defined as a ≥70% improvement in 1) swollen joint count (66 joints) and tender joint count (68 joints) (0 = Absent; 1 = Present) and 2) ≥70% improvement in 3 of the following 5 assessments: a) a participant's overall assessment of pain on a visual analog scale (VAS, no pain =0 to extreme pain =100); b) Patient's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100); c) Investigator's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100 ; d) participant's assessment of function across 8 functional areas as measured by Health Assessment Questionnaire (HAQ), total scores ranging from no difficulty =0 to inability to perform tasks =24; and e) serum C-Reactive Protein (decrease indicates improvement). This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving Hybrid ACR Response at Week 12
Lasso di tempo: Week 12
Hybrid ACR Response evaluates the improvement in active RA by combining elements of the ACR20/50/70 with a categorical score of the mean change in the core set measures (tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, disability index of the HAQ, and CRP). The mean percentage improvement from Baseline in the core set measures was computed and used with the participant's ACR20, ACR50, and ACR70 status to determine the hybrid ACR response in a lookup table. The range of values was -100 to 100, with a positive change indicating improvement. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving an ACR-N Response at Week 12
Lasso di tempo: Week 12
The ACR-N response is the minimum of the following: 1) the percent decrease from Baseline in tender joint counts (68 joints, 0 = absent, 1 = present); 2) the percent decrease from Baseline in swollen joint counts (66 joints, 0 = absent, 1 = present); and 3) the median percent decrease from Baseline for the following: a) Patient's Global Assessment of Pain (VAS, 0 mm = "no pain" and 100 mm = "extreme pain"); b) Patient's Global Assessment of Disease Activity (VAS, 0 mm = doing very well to 100 mm = doing very poor); c) Investigator's Global Assessment of Disease Activity (VAS, 0 mm = doing very well to 100 mm = doing very poor); d. physical function as measured by the HAQ (Likert scale, 0 to 3 with a lower score indicating less disability); and e) CRP. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving a DAS28-ESR Response at Week 12
Lasso di tempo: Week 12
The DAS28-ESR is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), ESR, and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-ESR = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.70 × ln (ESR) + 0.014 × GH. SQRT = square root. The DAS28-ESR is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. Depending upon the DAS28-ESR value for a given visit, change in DAS28-ESR is categorized as follows: No Response (reduction from Baseline ≤0.6), No response or Moderate Response (reduction >0.6 - 1.2), and Moderate or Good Response (reduction >1.2). The percentage of participants with a Moderate or Good change in DAS28-ESR was reported. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving a DAS28-CRP Response at Week 12
Lasso di tempo: Week 12
The DAS28-CRP is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), CRP, and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-CRP = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.36 × ln (CRP+1) + 0.014 × GH + 0.96. The DAS28-CRP is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. Depending upon the DAS28-CRP value for a given visit, change in DAS28-CRP is categorized as follows: No Response (reduction from Baseline ≤0.6), No response or Moderate Response (reduction >0.6 - 1.2), and Moderate or Good Response (reduction >1.2). The percentage of participants with a Moderate or Good change in DAS28-CRP was reported. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving DAS28-ESR Remission at Week 12
Lasso di tempo: Week 12
The DAS28-ESR is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), ESR, and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-ESR = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.70 × ln (ESR) + 0.014 × GH. SQRT = square root. The DAS28-ESR is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. DAS28-ESR remission is defined as a value <2.6 at the visit. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving DAS28-CRP Remission at Week 12
Lasso di tempo: Week 12
The DAS28-CRP is a continuous parameter derived from the formula: 0.56 × the square root of the tender joint count (0-28) + 0.28 × the square root of the swelling joint count (0-28) + 0.36 × the C reactive protein value (in mg/L +1) + 0.014 × Patient's Global Assessment of Disease Activity VAS of 0-100 mm + 0.96. The DAS28-CRP is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. DAS28-CRP remission is defined as a value <2.6 at the visit. This outcome measure applied to Base Study participants only.
Week 12
DAS28-ESR Area Under the Curve (AUC)
Lasso di tempo: Up to 12 weeks
DAS28-ESR AUC was to be calculated from the DAS28-ESR score versus time curve, which provided an assessment of changes in disease activity over time. The DAS28-ESR AUC was to be calculated using the trapezoidal rule as the DAS28-ESR multiplied by the duration of the assessment period (in weeks) and was to be expressed as %-weeks. A higher calculated AUC value indicates higher disease activity (worse). This outcome measure applied to Base Study participants only.
Up to 12 weeks
DAS28-CRP Area Under the Curve (AUC)
Lasso di tempo: Up to 12 weeks
DAS28-CRP AUC was to be calculated from the DAS28-CRP score versus time curve, which provided an assessment of changes in disease activity over time. The DAS28-CRP AUC was to be calculated using the trapezoidal rule as the DAS28-CRP multiplied by the duration of the assessment period (in weeks) and was to be expressed as %-weeks. A higher calculated AUC value indicates higher disease activity (worse). This outcome measure applied to Base Study participants only.
Up to 12 weeks
Change From Baseline in Tender Joint Count at Week 12
Lasso di tempo: Baseline and Week 12
Tender Joint Count was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A higher score indicated greater disease severity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in Swollen Joint Count at Week 12
Lasso di tempo: Baseline and Week 12
Swollen joint count included 66 joints (same joints as for tender joint count except this excluded evaluation of hips) that were assessed for the presence of swelling. Soft tissue swelling was considered to be present if there was palpable or visible evidence of capsular distention considered to be due to either synovial thickening and/or a joint effusion. Bony swelling, nodule formation, and joint deformity were excluded from consideration. A swollen joint was scored as 0 = Absent; 1 = Present for each joint. The overall swollen joint count ranged from 0 to 66. A higher score indicated greater disease severity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12
Lasso di tempo: Baseline and Week 12
SDAI is the simple linear sum of the following parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, Patient's Global Assessment of Disease Activity [PGA, VAS 0 to 10 cm], Investigator's Global Assessment of Disease Activity (MDGA, VAS 0 to 10 cm) and CRP levels (mg/dL). SDAI =TJC + SJC + PGA + MDGA + CRP. Overall scores can range from 0.0 to 86.0. A higher score indicated greater disease severity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Short Form Health Survey (SF-36) at Week 12
Lasso di tempo: Baseline and Week 12
The SF-36 is a health-related quality of life instrument that consists of 8 multi-item scales: limitations in physical functioning due to health problems, limitations in usual role activities due to physical health problems, bodily pain, general mental health (psychological distress and well-being), limitations in usual role activities due to personal or emotional problems, limitations in social functioning due to physical or mental health problems, vitality (energy and fatigue), and general health perception. Each scale is directly transformed into a 0 to 100 scale on the assumption that each question carries equal weight. The lower the score the greater the disability i.e., a score of 0 corresponds to maximum disability and a score of 100 corresponds to no disability. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 12
Lasso di tempo: Baseline and Week 12
The FACIT-F is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The higher the participant's response to the questions the greater the participant's fatigue. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Patient's Global Assessment of Disease Status/Activity (PGADSA) at Week 12
Lasso di tempo: Baseline and Week 12
A participant's overall assessment of pain was assessed from the amount of pain due to arthritis experienced during the past 48 hours on a VAS, where 0 mm = doing very well to 100 mm = doing very poor. A negative change from Baseline indicates improvement. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Investigator's Global Assessment of Disease Status/Activity (IGADSA) at Week 12
Lasso di tempo: Baseline and Week 12
The Investigator's Global Assessment of Disease Status/Activity (IGADSA) is measured with scores ranging from 0 to 100 mm (VAS, 0 mm = doing very well to 100 mm = doing very poor). A negative change from Baseline indicates improvement. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Patient's Global Assessment of Pain (PGAP) at Week 12
Lasso di tempo: Baseline and Week 12
A participant's overall assessment of pain was assessed from the amount of pain due to arthritis experienced during the past 48 hours on a VAS where 0 mm = "no pain" and 100 mm = "extreme pain". A negative change from Baseline indicates improvement. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Variazione rispetto al basale nel questionario di valutazione della salute sulla disabilità (indice di disabilità HAQ) alla settimana 12
Lasso di tempo: Basale e settimana 12
Lo stato funzionale del partecipante è stato valutato utilizzando l'indice di disabilità dell'HAQ su una scala Likert. Questo strumento di 20 domande valuta il grado di difficoltà che una persona ha nello svolgere compiti in 8 aree funzionali (vestirsi, alzarsi, mangiare, camminare, igiene, raggiungere, afferrare e attività della vita quotidiana). Le risposte in ciascuna area funzionale sono valutate da 0, che indica nessuna difficoltà, a 3, che indica l'incapacità di eseguire un compito in quell'area. Il punteggio complessivo per l'indice di disabilità è la media dei punteggi delle 8 aree funzionali e varia anch'esso da 0 a 3, con un punteggio più basso che indica meno disabilità. Una variazione negativa rispetto al valore di riferimento indica un miglioramento. Questa misura dell'esito si applicava solo ai partecipanti allo studio di base.
Basale e settimana 12
Change From Baseline in Serum C-Reactive Protein (CRP) at Week 12
Lasso di tempo: Baseline and Week 12
C-Reactive Protein is an inflammatory marker with a normal reference range of less than 0.9 mg/dL. Change from Baseline in CRP at Week 12 (Week 12 concentration minus Baseline concentration). This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 12
Lasso di tempo: Baseline and Week 12
The ESR is the rate at which red blood cells sediment in a period of one hour, and is a non-specific measure of inflammation. Change from Baseline is ESR at Week 12 minus ESR at Baseline. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in Hemoglobin at Week 12
Lasso di tempo: Baseline and Week 12
Hemoglobin is the iron-containing oxygen-transport metalloprotein in red blood cells. Change from Baseline is hemoglobin at Week 12 minus hemoglobin at Baseline. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Percentuale di partecipanti che hanno ottenuto una risposta ACR50 alla settimana 12
Lasso di tempo: Settimana 12
Le risposte ACR sono misurazioni numeriche del miglioramento in più criteri di valutazione della malattia. Una risposta ACR50 è definita come un miglioramento ≥50% in 1) conta delle articolazioni gonfie (66 articolazioni) e conta delle articolazioni dolenti (68 articolazioni) (0 = Assente; 1 = Presente) e 2) miglioramento ≥50% in 3 dei seguenti 5 valutazioni: a) la valutazione complessiva del dolore di un partecipante su una scala analogica visiva (VAS, nessun dolore = 0 a dolore estremo = 100); b) Valutazione globale del paziente dell'attività della malattia VAS (da molto bene =0 a molto scarso =100); c) Valutazione globale dell'attività della malattia da parte dello sperimentatore VAS (facendo molto bene = 0 a facendo molto male = 100; d) valutazione della funzione del partecipante in 8 aree funzionali misurata dal questionario di valutazione della salute (HAQ), punteggi totali che vanno da nessuna difficoltà = 0 all'incapacità di svolgere compiti =24; e e) proteina C-reattiva sierica (la diminuzione indica un miglioramento). Questa misura dell'esito si applicava solo ai partecipanti allo studio di base.
Settimana 12
Percentage of Participants With an ACR20 Response Over Time
Lasso di tempo: Week 1, Week 2, Week 4, Week 6, Week 18 and Week 24
ACR responses are numerical measurements of improvement in multiple disease assessment criteria. An ACR20 response is defined as a ≥20% improvement in 1) swollen joint count (66 joints) and tender joint count (68 joints) (0 = Absent; 1 = Present) and 2) ≥20% improvement in 3 of the following 5 assessments: a) a participant's overall assessment of pain on a visual analog scale (VAS, no pain =0 to extreme pain =100); b) Patient's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100); c) Investigator's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100 ; d) participant's assessment of function across 8 functional areas as measured by Health Assessment Questionnaire (HAQ), total scores ranging from no difficulty =0 to inability to perform tasks =24; and e) serum C-Reactive Protein (decrease indicates improvement). This outcome measure applied to Base Study participants only.
Week 1, Week 2, Week 4, Week 6, Week 18 and Week 24

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Merck Sharp & Dohme LLC

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 maggio 2012

Completamento primario (Effettivo)

3 ottobre 2013

Completamento dello studio (Effettivo)

3 ottobre 2013

Date di iscrizione allo studio

Primo inviato

30 marzo 2012

Primo inviato che soddisfa i criteri di controllo qualità

30 marzo 2012

Primo Inserito (Stima)

2 aprile 2012

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

27 marzo 2019

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 marzo 2019

Ultimo verificato

1 marzo 2019

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • P08683 (Altro identificatore: Merck)
  • MK-8457-008 (Altro identificatore: Merck)
  • 2012-000439-17 (Numero EudraCT)
  • 132235 (Identificatore di registro: JAPIC-CTI)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Sì

Descrizione del piano IPD

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Artrite reumatoide (AR)

Prove cliniche su MK-8457 100 mg

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Myanmar

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi